Tao Synergies | 10-Q: FY2025 Q3 Revenue: USD 203.37 K

Revenue: As of FY2025 Q3, the actual value is USD 203.37 K.

EPS: As of FY2025 Q3, the actual value is USD -1.56.

EBIT: As of FY2025 Q3, the actual value is USD -1.843 M.

Revenues from TAO staking: $203,371 for the three months ended September 30, 2025, and $207,333 for the nine months ended September 30, 2025.

Research and Development Expenses: $54,388 for the three months ended September 30, 2025, compared to $222,897 for the same period in 2024. For the nine months ended September 30, 2025, R&D expenses were $263,759 compared to $1,174,214 for the same period in 2024.
General and Administrative Expenses: $1,948,483 for the three months ended September 30, 2025, compared to $1,136,772 for the same period in 2024. For the nine months ended September 30, 2025, G&A expenses were $5,148,227 compared to $3,457,916 for the same period in 2024.
Warrant Issuance Costs: $0 for the three months ended September 30, 2025, compared to $618,375 for the same period in 2024. For the nine months ended September 30, 2025, warrant issuance costs were $699,845 compared to $618,375 for the same period in 2024.
Net Loss: - $3,923,247 for the three months ended September 30, 2025, compared to - $5,742,013 for the same period in 2024. For the nine months ended September 30, 2025, net loss was - $21,054,156 compared to - $7,222,021 for the same period in 2024.

Net Cash Used in Operating Activities: - $3,944,213 for the nine months ended September 30, 2025, compared to - $3,716,123 for the same period in 2024.
Net Cash Used in Investing Activities: - $17,570,203 for the nine months ended September 30, 2025, compared to - $1,000,000 for the same period in 2024.
Net Cash Provided by (Used in) Financing Activities: $5,303,622 for the nine months ended September 30, 2025, compared to - $4,319,595 for the same period in 2024.

Unrealized Loss on Digital Assets: - $2,382,129 for the three months ended September 30, 2025, and - $2,396,497 for the nine months ended September 30, 2025.
Change in Fair Value of Warrant Liability: $109,090 for the three months ended September 30, 2025, compared to - $218,000 for the same period in 2024. For the nine months ended September 30, 2025, the change was - $13,055,585 compared to - $314,000 for the same period in 2024.
Change in Fair Value of Derivative Liability: $106,000 for the three months ended September 30, 2025, compared to - $22,000 for the same period in 2024. For the nine months ended September 30, 2025, the change was - $76,000 compared to $1,091,000 for the same period in 2024.

Core Business Focus: The company plans to continue its cryptocurrency treasury strategy focused on the acquisition and staking of the TAO token. Approximately 88% of the company’s treasury holdings were invested in TAO as of September 10, 2025, with plans to continue allocating substantial portions of excess cash to TAO without a formal cap on the percentage of treasury invested.
Non-Core Business: The company is evaluating its strategy for Bryostatin-1, its novel drug candidate targeting the activation of Protein Kinase C Epsilon, and expects to need additional capital to continue pursuing its TAO treasury strategy.
Priority: Emphasis on maximizing tokens per share through a long-only TAO accumulation policy and exploring additional yield-enhancement strategies, including participation in TAO subnets.